- Home
- PROV vs ENTX Comparison
PROV vs ENTX Comparison
Compare PROV & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROV
- ENTX
- Stock Information
- Founded
- PROV 1956
- ENTX 2010
- Country
- PROV United States
- ENTX Israel
- Employees
- PROV N/A
- ENTX N/A
- Industry
- PROV Savings Institutions
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PROV Finance
- ENTX Health Care
- Exchange
- PROV Nasdaq
- ENTX Nasdaq
- Market Cap
- PROV 100.7M
- ENTX 104.0M
- IPO Year
- PROV 1996
- ENTX 2018
- Fundamental
- Price
- PROV $15.70
- ENTX $1.72
- Analyst Decision
- PROV Hold
- ENTX Strong Buy
- Analyst Count
- PROV 1
- ENTX 1
- Target Price
- PROV $16.00
- ENTX $10.00
- AVG Volume (30 Days)
- PROV 6.6K
- ENTX 36.8K
- Earning Date
- PROV 07-28-2025
- ENTX 08-08-2025
- Dividend Yield
- PROV 3.57%
- ENTX N/A
- EPS Growth
- PROV N/A
- ENTX N/A
- EPS
- PROV 0.97
- ENTX N/A
- Revenue
- PROV $39,909,000.00
- ENTX $223,000.00
- Revenue This Year
- PROV $3.06
- ENTX N/A
- Revenue Next Year
- PROV $9.15
- ENTX N/A
- P/E Ratio
- PROV $16.18
- ENTX N/A
- Revenue Growth
- PROV 1.24
- ENTX N/A
- 52 Week Low
- PROV $12.01
- ENTX $1.41
- 52 Week High
- PROV $16.70
- ENTX $2.79
- Technical
- Relative Strength Index (RSI)
- PROV 54.81
- ENTX 35.45
- Support Level
- PROV $15.25
- ENTX $1.75
- Resistance Level
- PROV $15.90
- ENTX $1.88
- Average True Range (ATR)
- PROV 0.47
- ENTX 0.11
- MACD
- PROV 0.01
- ENTX -0.02
- Stochastic Oscillator
- PROV 77.53
- ENTX 0.00
About PROV Provident Financial Holdings Inc.
Provident Financial Holdings Inc is a holding company of Provident Savings Bank, F.S.B. Through the bank, it is engaged in providing community and mortgage banking services to consumers and small to mid-sized businesses in the Inland Empire region of Southern California. The company's business segment is Bank. The Bank's activities include attracting deposits, offering banking services, and originating and purchasing single-family, multi-family, commercial real estate, construction, and other mortgage loans and, to a lesser extent, commercial business and consumer loans held for investment.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.